---
title: "Sequoia China announces the completion of the acquisition of global business for Moxifloxacin"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/274576310.md"
description: "Sequoia China completed the global business acquisition of the fluoroquinolone antibiotic moxifloxacin on February 3rd, establishing Hangzhou ShanZe Biopharmaceutical Co., Ltd. and its parent company Ascenda Pte. Ltd., focusing on the fields of anti-infection and respiratory. ShanZe Biopharmaceutical and Ascenda acquired specific assets of BaiFuLe®, including drug registration certificates, intellectual property, and business contracts"
datetime: "2026-02-03T00:39:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274576310.md)
  - [en](https://longbridge.com/en/news/274576310.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274576310.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/274576310.md) | [繁體中文](https://longbridge.com/zh-HK/news/274576310.md)


# Sequoia China announces the completion of the acquisition of global business for Moxifloxacin

36Kr learned that Sequoia China announced that it has officially completed the global acquisition of the core product of fluoroquinolone antibiotics, moxifloxacin (brand name: Avelox®), along with related businesses and assets on February 3rd. It has established an innovative biopharmaceutical company, Hangzhou ShanZe Biopharmaceutical Co., Ltd., focused on anti-infection and respiratory fields, with its parent company Ascenda Pte. Ltd. responsible for the operation of this business. According to the agreement, ShanZe Biopharmaceutical and its parent company Ascenda Pte. Ltd. have acquired specific assets of Avelox® globally, including drug registration certificates, intellectual property, and business contracts in relevant countries and regions

### 相关股票

- [Bayer (BAYRY.US)](https://longbridge.com/zh-CN/quote/BAYRY.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [ProShares Ultra Health Care ETF (RXL.US)](https://longbridge.com/zh-CN/quote/RXL.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md)

## 相关资讯与研究

- [Bayer - AskBio announces completion of enrollment in phase 2 clinical trial of AB-1002](https://longbridge.com/zh-CN/news/281314240.md)
- [Bayer Reaffirms Pharma Targets, Aiming for 30% Margin](https://longbridge.com/zh-CN/news/281359378.md)
- [Bayer Announces Approval Of New Indication For Kerendia In The EU](https://longbridge.com/zh-CN/news/280969658.md)
- [Teva Pharmaceutical Gets US FDA Approval for Prolia Biosimilar; Xoliar Biosimiliar Applications Accepted in US, Europe](https://longbridge.com/zh-CN/news/281026919.md)
- [EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025](https://longbridge.com/zh-CN/news/281015927.md)